Clotblog with Dr Samuel GoldhaberView all posts »
Rosuvastatin in the prevention of venous thromboembolismMay 29, 2009 11:45 EDT
What are the implications of the JUPITER trial's landmark findings in preventing venous thromboembolism? A 43% highly significant reduction in incidence and no increased bleeding risk with rosuvastatin 20 mg daily compared with placebo. Where do we go next? And what do we do now in clinical practice?
Please refer to the epublished JUPITER manuscript: Glynn RJ et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; March 29.